BioSpace News Archive

symplr®, the leader in enterprise healthcare operations including governance, risk management and compliance (“GRC”) SaaS solutions, backed by Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”) and Charlesbank Capital Partners (“Charlesbank”), announced today that it has agreed to acquire Halo Health.

Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced the formation of and initial appointments to its Scientific Advisory Board (SAB).

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presentation of data for eprenetapopt in combination with pembrolizumab for the treatment of advanced solid tumors at the European Society of Medical Oncology (ESMO) Congress 2021 from September 16 – 21, 2021.

Centene Corporation issued a reminder that it will release its 2021 third quarter financial results at approximately 6 a.m. on Tuesday, October 26, 2021, and host a conference call afterwards at approximately 8:30 a.m. to review the results.

Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced the initiation of a Phase 2a clinical study to evaluate the safety and efficacy of PCN-101 (R-ketamine).

DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, announced the appointment of David Liebowitz, M.D., Ph.D., an industry veteran with over 20 years of experience in oncology drug and viral vaccine development, as chief medical officer.

The Gilbert Family Foundation, a private nonprofit established by Jennifer and Dan Gilbert to accelerate a cure for neurofibromatosis type 1, announced funding of a new $5.4 million clinical study.

CalciMedica Inc. (“CalciMedica” or the “Company”), the CRAC channel company, today announced the results from CARDEA, a Phase 2 trial of its lead drug candidate Auxora™ in patients with severe COVID-19 pneumonia.

Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology, today announced the expansion of the Company’s executive management team.

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach.